Clay Siegall

ADC, Easy As 123 with Seattle Genetics’ Clay Siegall

When it comes to finding cures for cancer and providing life saving cancer treatment, Dr. Clay Siegall and his company Seattle Genetics are among some of the most prominent around. In 1998, Dr. Siegall co-founded Seattle Genetics. Throughout the years, they’ve pioneered antibody-based cancer therapies. In addition, Dr. Siegall managed to raise $675 million in capital for the company. Dr. Siegall’s determination and research led to providing life saving treatment to thousands of people.
It takes skill to raise capital in such a manner that Dr. Siegall has managed to do. Very few people have that drive. Prior to co-founding the company, Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He is also the board of directors of Alder Biopharmecuticals. To top it all off, Dr. Siegall holds more than 15 different patents and is the author of more than 70 publications. In a matter of years, Seattle genetics has managed to achieve what very few companies have, which is sustainability.
Time and time again the company has thrived under tumultuous circumstances. Since the distribution of their live saving drug ADCTERIS hit the market shelves, it has gone off to critical acclaim, achieving record sales. In addition, Seattle Genetics also has around 25 ADCs in the works. In 2016 alone, the company expects to increase revenue from $390 milion to $430 million. The aforementioned ADCs may very well become the company’s best sources of revenue. The tenacity of Seattle is evident as they continue to develop more life saving compounds.

Sources:

http://seekingalpha.com/article/3991804-seattle-genetics-sgen-clay-b-siegall-q2-2016-results-earnings-call-transcript

https://www.crunchbase.com/person/clay-b-siegall#/entity

Seattle Genetics Produces Innovate Cancer Fighting Therapies

Battling cancer is the stock in trade of Seattle Genetics. From its headquarters in Bothell, Washington the biotechnology company has been developing innovative antibody based cancer treatments since 1998. Today they are the industry leader in the creation and commercialization of antibody drug conjugates or ADC. The technology harnesses the ability of monoclonal antibodies to target and deliver agents to kill cancer cells. Some of the strengths of the treatment is that it doesn’t damage the healthy cells, enhances anti-tumor activity and eliminates the toxic effects normally associated with chemotherapy.

Seattle Genetics also partners with a number of companies to give people around the world access to their groundbreaking therapies. Currently the ADC treatment they have developed is used in 60 countries. Some of the companies with which they have collaborated to market their antibody-based therapies include Takeda Pharmaceutical Company, Pfizer, Genentech, GlaxoSmithKline and AbbVie. This is important because their ADC therapy is one of the first new cancer treatments in over 30 years. Seattle Genetics also has a number of very promising therapies in their product pipeline

Dr. Clay Siegall, Co-Founder, CEO, and President of Seattle Genetics, has played a very important role in the company’s amazing growth. An innovative scientist long focused on rigorous research combined with drug development and testing, he built the company on scientific innovation. He also secured $1.2 billion in financing and FDA approval for ADCETRIS, their proprietary ADC product. Dr. Clay Siegall has been involved in cancer research for many years. Before co-founding Seattle Genetics, he worked with the National Institutes of Health, the National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute.

After earning a University of Maryland undergrad degree in Zoology and a Genetics doctorate from George Washington University, he’s had his work published in more than 70 publications. He is a member of numerous biotech company boards and holds 15 patents. Dr. Siegall has also won several awards for his work on cancer research. At Seattle Genetics he leads a staff that includes over 800 employees that are passionate about trying to find new ways to help people living with cancer.

Learn more about Clay Siegall

http://www.ultragenyx.com/about/board/siegall/

http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS-Interview-Siegall.pdf